If you have ever read a health headline comparing heart disease statistics to cancer mortality, or been told you have an elevated “cardiovascular risk” without quite understanding what that means, you have encountered a terminology question that many people — including some in medicine — answer imprecisely. Heart disease and cardiovascular disease are related, frequently conflated, and consistently misunderstood, and the difference between them has practical consequences for understanding health statistics, medical diagnoses, and what risk factors your doctor is actually assessing.
The Short Answer
Cardiovascular disease is the umbrella term. Heart disease is a subset within it.
The word “cardiovascular” combines “cardio” (heart) and “vascular” (blood vessels). Cardiovascular disease (CVD) therefore refers to all diseases and disorders of both the heart and the blood vessels — including the arteries and veins that supply the brain, the legs, the kidneys, and every other organ in the body.
“Heart disease” refers more specifically to conditions affecting the heart itself: its muscle, its electrical system, its valves, and its own blood supply (the coronary arteries). Every case of heart disease is, by definition, a form of cardiovascular disease. But not every form of cardiovascular disease is heart disease — stroke, for example, is cardiovascular disease but is not heart disease.
Think of it as two concentric circles: cardiovascular disease is the outer circle; heart disease is an inner circle within it.
What Is Included in “Heart Disease”?
“Heart disease” is itself an umbrella term covering a range of conditions affecting the heart’s structure and function. When the term appears in casual conversation, it most commonly refers to coronary artery disease — the buildup of atherosclerotic plaques in the arteries that supply blood to the heart muscle, which can cause angina (chest pain) and heart attacks. But the medical category “heart disease” encompasses considerably more:
Coronary artery disease (CAD) is the most common form of heart disease and the most common cause of death in most high-income countries. It results from atherosclerosis in the coronary arteries, progressively narrowing these vessels until either the narrowing limits blood flow enough to produce symptoms (stable angina) or a plaque ruptures and triggers acute clot formation (myocardial infarction).
Heart failure is the condition in which the heart cannot pump enough blood to meet the body’s needs — whether because it pumps too weakly (HFrEF, ejection fraction below 40 percent) or because it has become too stiff to fill normally (HFpEF). Heart failure is often a consequence of coronary artery disease or hypertension.
Cardiac arrhythmias are disorders of the heart’s electrical system, producing abnormal rhythms: atrial fibrillation (the most common sustained arrhythmia), ventricular tachycardia (which can progress to ventricular fibrillation and cardiac arrest), heart block, and others.
Valvular heart disease includes disorders of the four heart valves that cause stenosis (narrowing) or regurgitation (leaking). The most common conditions in older adults are aortic stenosis (progressive calcification of the aortic valve) and mitral regurgitation.
Cardiomyopathy refers to diseases of the heart muscle itself: dilated (enlarged, weakened heart), hypertrophic (abnormal thickening — the most common genetic cardiovascular disease and the leading cause of sudden cardiac death in young athletes), and restrictive (stiff heart from infiltrative conditions like amyloidosis).
Congenital heart defects are structural abnormalities present from birth, affecting approximately 1 percent of all live births.
Pericardial disease involves the fibrous sac surrounding the heart, including pericarditis, pericardial effusion, and constrictive pericarditis.
Endocarditis is infection of the inner lining of the heart, most commonly affecting the heart valves when bacteria enter the bloodstream and adhere to damaged valve tissue.
What Is Added in “Cardiovascular Disease”?
Cardiovascular disease includes all of the above, plus disorders of the blood vessels throughout the body that do not directly affect the heart:
Cerebrovascular disease encompasses all conditions affecting the blood vessels of the brain: ischemic stroke (the most common type, caused by a clot blocking a cerebral artery), hemorrhagic stroke (rupture of a cerebral blood vessel, most often due to poorly controlled hypertension), and transient ischemic attacks (TIAs, or “mini-strokes”).
Peripheral artery disease (PAD) is atherosclerosis of the arteries supplying the limbs. It produces symptoms from claudication (reproducible leg pain with walking) to critical limb ischemia. PAD is a marker of systemic atherosclerosis — most patients with PAD also have significant coronary and cerebrovascular atherosclerosis.
Aortic disease includes aortic aneurysm (abnormal dilation of the aorta, the body’s largest artery) and aortic dissection (an acute tear in the aortic wall, one of the most dangerous cardiovascular emergencies).
Renal artery stenosis is atherosclerotic narrowing of the arteries supplying the kidneys, causing secondary hypertension and contributing to chronic kidney disease.
Depending on the definition used, cardiovascular disease may also include venous thromboembolism (VTE): deep vein thrombosis (DVT) and pulmonary embolism (PE).
Why Health Organizations Use the Terms Differently
One reason this distinction causes confusion is that major health organizations use these terms with different scopes, producing statistics that appear inconsistent.
The CDC reports heart disease and stroke as separate categories in US mortality statistics. When the CDC states “heart disease is the leading cause of death in the United States,” it counts deaths from coronary artery disease, heart failure, arrhythmias, and other heart-specific conditions — but NOT stroke, which is counted separately as the fifth leading cause of death.
The AHA uses “cardiovascular disease” to combine heart disease AND stroke. AHA statistics combining both conditions produce the most commonly cited figure that cardiovascular disease kills more Americans than all cancers combined.
The WHO uses “cardiovascular diseases” as the broadest category — encompassing all diseases of heart and blood vessels globally — producing the figure of approximately 17.9 million global cardiovascular deaths per year.
A practical check: if a health statistic includes stroke, it is using the broader cardiovascular definition. If stroke is reported separately, it is using the narrower heart disease definition.
Coronary Artery Disease, Coronary Heart Disease, Ischemic Heart Disease: Are These the Same?
These three terms are frequently used interchangeably and refer to the same underlying condition — atherosclerosis of the coronary arteries — with minor differences in emphasis:
Coronary artery disease (CAD) is the preferred contemporary term in American cardiology, emphasizing the anatomical site (coronary arteries) and the disease process (atherosclerosis).
Coronary heart disease (CHD) is the older term, still widely used in British medicine, international epidemiology, and older literature, emphasizing the heart as the organ affected.
Ischemic heart disease (IHD) is the WHO and ICD-preferred term, emphasizing the functional consequence: myocardial ischemia (insufficient blood flow to the heart muscle). IHD is slightly broader in that it can include rare non-atherosclerotic causes of coronary ischemia, but in clinical practice the terms are used synonymously.
Does the Distinction Affect Treatment or Screening?
For everyday clinical care, the practical difference is limited — because the shared risk factors (hypertension, dyslipidemia, diabetes, smoking, inactivity) and shared preventive strategies (blood pressure control, statins, antiplatelet therapy, lifestyle modification) apply to the entire cardiovascular spectrum. Treating hypertension benefits both heart attack and stroke prevention simultaneously.
Where the distinction matters is in risk calculation. The Pooled Cohort Equations (PCE), the most widely used cardiovascular risk tool in American preventive medicine, calculate the 10-year risk of a first “atherosclerotic cardiovascular disease event” — defined as nonfatal MI, fatal coronary heart disease, or fatal or nonfatal stroke. A PCE result of 10 percent means a 10 percent chance of experiencing a heart attack OR stroke over 10 years.
Some older risk calculators calculated only coronary event risk (not stroke). The move to cardiovascular-inclusive risk estimation matters particularly for women and individuals with elevated blood pressure, where the stroke contribution to total cardiovascular risk is proportionally larger.
The ACC/AHA 2019 cardiovascular prevention guidelines use ASCVD risk — which includes stroke — to determine who benefits from statin therapy. Statin decisions are therefore based on combined heart attack and stroke risk, not heart attack risk alone.
What Should Patients Make of These Terms?
If you are told you have “heart disease,” the most important next question is: which specific condition? Coronary artery disease, heart failure, atrial fibrillation, and valvular disease each have distinct treatments, monitoring requirements, and implications for family members. “Heart disease” alone does not specify enough for informed decision-making.
If you are told you have an elevated “cardiovascular risk,” the scope of that risk assessment includes both heart attack and stroke. The lifestyle interventions and medications that reduce that risk address both conditions simultaneously, because most risk factors operate through the same biological mechanisms — atherosclerosis, hypertension, and inflammation — regardless of whether a future event occurs in the coronary arteries or the cerebral arteries.
If you have a family history of “heart problems,” it is worth clarifying whether those problems were heart attacks, strokes, heart failure, or arrhythmias — because while the shared cardiovascular risk framework applies to most, specific family histories carry different genetic implications and may trigger different screening approaches.
For a comprehensive overview of cardiovascular disease and its many types, see our article on what is cardiovascular disease. For everyday practical guidance on protecting heart and vascular health, see what is heart health. To understand the anatomy underlying these conditions, see our guide to how the heart works.
Sources: CDC — Heart Disease | American Heart Association | World Health Organization — Cardiovascular Diseases
How the Shared Root of Atherosclerosis Connects Heart Disease and Stroke
One of the most clinically useful insights in cardiovascular medicine is that heart disease and stroke — despite being categorized separately in mortality statistics — share a single dominant underlying cause: atherosclerosis. The same process that narrows coronary arteries and causes heart attacks is occurring simultaneously in carotid arteries (supplying the brain), in peripheral arteries (supplying the legs), and in the aorta. Atherosclerosis is a systemic disease of the entire arterial system, not a localized process confined to the vessels of the heart.
This means that a person diagnosed with coronary artery disease (heart disease) has a substantially elevated risk of ischemic stroke — not because heart disease causes stroke, but because the same pathological process is almost certainly present in the cerebrovascular circulation as well, even if not yet symptomatic. This is why patients after a heart attack receive antiplatelet therapy (aspirin, often combined with a P2Y12 inhibitor like clopidogrel) that also reduces stroke risk; why they receive statins that reduce both coronary and cerebrovascular events; and why blood pressure control in these patients benefits both the coronary and cerebrovascular circulation.
The concept of “polyvascular disease” — atherosclerosis clinically expressed in more than one vascular bed — is associated with particularly high cardiovascular risk. A person with both coronary artery disease and peripheral artery disease has a higher annual risk of heart attack, stroke, and cardiovascular death than someone with coronary artery disease alone. Recognizing the systemic nature of atherosclerosis helps explain why “cardiovascular risk” is more clinically useful as a unified concept than “heart disease risk” and “stroke risk” computed separately.
Risk Factor Differences Between Heart Disease and Stroke
While atherosclerosis is the shared root, the relative contribution of specific risk factors differs meaningfully between coronary artery disease and ischemic stroke, and understanding these differences can inform individualized prevention strategies.
Hypertension is the single most important modifiable risk factor for ischemic stroke — more potent than LDL cholesterol in the cerebrovascular circulation, where vessel wall stress from chronically elevated blood pressure directly injures small and medium cerebral arteries. Blood pressure reduction produces greater relative risk reduction for stroke than for coronary events. This is why aggressive blood pressure treatment is particularly important for stroke prevention.
LDL cholesterol is proportionally more important for coronary artery disease. High-intensity statin therapy produces greater relative risk reduction for coronary events than for ischemic stroke, though statins do reduce stroke risk (partly through LDL lowering and partly through anti-inflammatory and plaque-stabilizing effects).
Atrial fibrillation is uniquely important for cardioembolic stroke — stroke caused by a clot forming in the heart (specifically in the left atrial appendage when the atria fail to contract normally) that travels to the brain. AF approximately quintuples stroke risk and is managed with anticoagulation (not antiplatelet therapy alone) specifically to prevent cardioembolic stroke. AF does not directly cause heart attack — though it does reduce cardiac output, can exacerbate angina in patients with coronary artery disease, and is associated with heart failure.
Diabetes doubles to quadruples cardiovascular risk overall, but has particularly pronounced effects on smaller blood vessels — which explains why diabetes is especially strongly associated with microvascular disease (retinopathy, nephropathy, peripheral neuropathy) and with lacunar stroke (small vessel cerebrovascular disease), as well as with a pattern of diffuse, multi-vessel coronary artery disease that is often technically challenging to revascularize.
Secondary Prevention: Different Emphases for Heart Disease vs. Stroke
After a first cardiovascular event, secondary prevention strategies share a common foundation but have condition-specific components:
After a heart attack: dual antiplatelet therapy (aspirin + P2Y12 inhibitor for 12 months), high-intensity statin, ACE inhibitor or ARB (particularly with reduced ejection fraction or diabetes), beta-blocker (especially with reduced EF), and cardiac rehabilitation. The goal is preventing recurrent coronary events and the development of heart failure.
After an ischemic stroke: antiplatelet therapy (single antiplatelet — usually aspirin, or clopidogrel, or dipyridamole-aspirin; NOT dual antiplatelet for most patients long-term), statin, aggressive blood pressure reduction (target typically below 130/80 mmHg), and neurological rehabilitation. If the stroke is cardioembolic from AF, anticoagulation (DOAC or warfarin) replaces antiplatelet therapy.
The difference in antiplatelet approach highlights an important distinction: after a heart attack, dual antiplatelet therapy is beneficial because of the high risk of stent thrombosis and recurrent acute coronary events; after a non-cardioembolic stroke, prolonged dual antiplatelet therapy generally increases bleeding risk without a clear benefit over single antiplatelet therapy. The clinical mechanisms of recurrent event risk differ between coronary and cerebrovascular disease, producing different treatment protocols despite the same shared risk factors.
Genetic Contributors to Heart Disease vs. Cardiovascular Disease
The genetic architecture of cardiovascular disease is complex and incompletely characterized, but some important patterns have emerged that differ between heart disease subtypes and broader cardiovascular conditions.
Familial hypercholesterolemia (FH) — caused by mutations in the LDL receptor gene (most commonly), apolipoprotein B, or PCSK9 — dramatically elevates LDL cholesterol from birth (LDL-C levels typically 190–400 mg/dL) and produces premature coronary artery disease (heart attacks in men in their 30s and 40s, women in their 40s and 50s). FH is autosomal dominant, affecting roughly 1 in 250 people in the general population — making it one of the most common monogenic disorders — yet remains vastly underdiagnosed. Family members of people diagnosed with FH should be screened.
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disease, caused by mutations in sarcomere proteins (most commonly MYH7 and MYBPC3), with autosomal dominant inheritance. It affects approximately 1 in 500 people and is the leading cause of sudden cardiac death in young athletes. Genetic testing and family screening are standard practice when HCM is identified in a proband.
Long QT syndrome, Brugada syndrome, and other inherited arrhythmia syndromes carry risk of dangerous ventricular arrhythmias and sudden cardiac death without structural heart disease. These are purely electrical conditions — the heart’s anatomy is normal — and require a different diagnostic and management approach from structural heart disease.
For hypertension and stroke, genetic contributions are real but primarily polygenic — many common genetic variants of small individual effect, interacting with lifestyle and environmental factors. No single high-impact gene dominates the architecture of stroke risk the way LDL receptor mutations dominate the architecture of premature coronary artery disease. This means that for most people, stroke risk is more modifiable through lifestyle and blood pressure management than through genetic screening.
What the Terms Mean When You See Them in Your Medical Records
When a diagnosis appears in your medical record or discharge summary, the specific term used carries more clinical precision than the lay usage of “heart disease” or “cardiovascular disease” would suggest. Understanding what specific diagnoses mean helps patients engage more effectively with their own care.
“Coronary artery disease” or “CAD” in a medical record typically means your physician has identified atherosclerosis in the coronary arteries, confirmed by coronary angiography, CT coronary angiography, or a coronary calcium score above zero. It does not specify the severity or whether you have had a heart attack. Ask your physician which arteries are affected, how severely, and whether the degree of narrowing warrants intervention or medication management.
“Ischemic heart disease” or “IHD” is the ICD-10 billing code equivalent and is synonymous with coronary artery disease in nearly all contexts. If you see this on a billing statement or insurance document, it refers to the same condition as CAD.
“Cardiovascular disease” as a risk category (e.g., “you are at high cardiovascular risk”) refers to your predicted probability of experiencing a cardiovascular event — heart attack or stroke — over a defined time period. It does not mean you currently have cardiovascular disease; it describes your risk of developing it. The distinction between “having cardiovascular disease” and “being at high cardiovascular risk” is clinically important: both may justify medications like statins, but the urgency and intensity of treatment differ.
“Heart failure” is one of the most misunderstood diagnoses in medicine. It does not mean the heart is about to stop. It means the heart is not functioning at full capacity and the body is compensating in ways that eventually cause symptoms. Many people with heart failure live for years or decades with good quality of life when the condition is well-managed with appropriate medications and lifestyle measures.
Closing: The Shared Goal of Heart and Vascular Health
Whether we use the term “heart disease” or “cardiovascular disease” matters less than understanding that the conditions these terms describe are connected — by shared risk factors, shared biological mechanisms, shared prevention strategies, and shared treatment principles. The person working to control their blood pressure is protecting both their coronary arteries and their cerebral arteries simultaneously. The person who stops smoking reduces their risk of heart attack, stroke, peripheral artery disease, and aortic aneurysm in a single intervention. The statin prescribed after a heart attack also reduces the risk of the next stroke.
This interconnectedness is medicine’s most efficient insight in cardiovascular prevention: the lifestyle choices and treatments that prevent one cardiovascular condition generally prevent most others, because they target the systemic biological processes — atherosclerosis, inflammation, and endothelial dysfunction — that underlie the entire spectrum of cardiovascular disease. Understanding that heart disease and cardiovascular disease are related but not identical helps navigate the terminology — and understanding that they share the same root helps motivate the interventions that matter most.